A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525617-31-00

Enrollment

225

Registered

2026-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Brief summary

Time from randomization to the date of death (any cause).

Detailed description

CCI, CCI, CCI, CCI, Changes in participant quality of life evaluated by questionnaire

Interventions

DRUGGEMCITABINE

DRUGPACLITAXEL

DRUGAtebimetinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time from randomization to the date of death (any cause).	—

Secondary

Measure	Time frame
CCI, CCI, CCI, CCI, Changes in participant quality of life evaluated by questionnaire	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 19, 2026